Stanley Laman Group Ltd. acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,023 shares of the biopharmaceutical company’s stock, valued at approximately $219,000.

Several other institutional investors and hedge funds have also made changes to their positions in ALNY. Baillie Gifford & Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 19.8% in the 1st quarter. Baillie Gifford & Co. now owns 5,684,504 shares of the biopharmaceutical company’s stock worth $531,217,000 after acquiring an additional 937,654 shares during the last quarter. FMR LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 5.2% in the 1st quarter. FMR LLC now owns 15,945,666 shares of the biopharmaceutical company’s stock worth $1,490,122,000 after acquiring an additional 791,113 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 4.6% in the 1st quarter. BlackRock Inc. now owns 6,428,127 shares of the biopharmaceutical company’s stock worth $600,707,000 after acquiring an additional 282,322 shares during the last quarter. Coronation Fund Managers Ltd. bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth approximately $11,789,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 579.8% in the 1st quarter. SG Americas Securities LLC now owns 133,828 shares of the biopharmaceutical company’s stock worth $12,506,000 after acquiring an additional 114,143 shares during the last quarter. Hedge funds and other institutional investors own 89.95% of the company’s stock.

NASDAQ ALNY traded down $1.10 during trading on Thursday, hitting $77.95. The company had a trading volume of 4,523 shares, compared to its average volume of 784,727. The company has a current ratio of 6.28, a quick ratio of 6.16 and a debt-to-equity ratio of 0.17. Alnylam Pharmaceuticals, Inc. has a one year low of $60.27 and a one year high of $124.21. The firm has a market capitalization of $8.77 billion, a P/E ratio of -10.40 and a beta of 2.46. The stock has a fifty day simple moving average of $74.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The business had revenue of $38.20 million during the quarter, compared to analyst estimates of $42.24 million. During the same period in the prior year, the business earned ($1.61) EPS. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -8.21 EPS for the current fiscal year.

A number of brokerages have recently weighed in on ALNY. Barclays restated a “buy” rating and issued a $125.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, August 7th. Cowen lowered their price objective on shares of Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 8th. Goldman Sachs Group restated a “neutral” rating and issued a $80.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, May 23rd. Finally, BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $126.00 to $128.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Six analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $121.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

See Also: Asset Allocation and Your Retirement

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.